Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Endostar with Dacarbazine and Cisplatin in Metastatic Melanoma
NCT03095079Phase 2Unknown
- Sponsor
- Peking University Cancer Hospital & Institute
- Start
- Oct 2016
- Primary completion
- Dec 2017
- Modality
- rProtein (Recombinant Protein), Biologic
- Countries
- 1
01
Overview
A Phase 2 trial of endostar in melanoma, sponsored by Peking University Cancer Hospital & Institute. Status: unknown.
02
Drugs
endostar
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT03095079.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03095079.